# RHENMAN HEALTHCARE EQUITY L/S FUND

# **OUTSTANDING LONG-TERM PERFORMANCE IN A COMPLEX MARKET**

- Annualised return of 19% (net) since inception
- Over 20 years managing successful healthcare funds.
- World renowned industry professionals each with over 30 years experience, actively involved through the Scientific Advisory Board.
- Unquestionable alpha generation, outperforming all relevant indices and top quartile in all relevant rankings.
  - Long term investment horizon:
    - Diversified across subsectors, company size and geographies to lower volatility.
    - Active trading around holdings.
    - Predominantly cash flow positive companies.
    - Typically investing post approval, mitigating event risk.

#### MONTHLY UPDATE

February was another volatile month for global stock markets. After falling by almost eight percent during the early part of the month, markets recovered and a global equity index closed down by about 1%. Healthcare was down about 1.5% and biotechnology was down 5%. The fund's main share class, IC1 (EUR), was down by 5%. The negative interpretations, which have characterized stock market spectators worldwide since last spring, continued. In addition to the already known sources of concern (such as China, commodity prices, Syria and economic growth worries), nervousness over the stability and strength of the banking system was a novel factor this time around. Bank shares across the globe, and especially in Europe, fell sharply due to growing uncertainty over banks' profitability in a prolonged period of ultralow interest rates and also financing structures. Even if these concerns proves in all probability to be unfounded, the strong market reactions were yet another sign of investors' risk aversion and their fears of deflation. The ongoing US primary campaigns, where populist messages have dominated the debate, in addition to the uncertain outcome of the upcoming British EU referendum, also had a dampening effect on stock markets. After a slight recovery in oil prices, and as the reporting season began to come to an end, the market turned upwards in the middle of February; a time coinciding with when American companies were able to resume their share buybacks and also with increased insider buying. The recovery was almost as sharp as the preceding downturn.

Healthcare continued to be a bifurcated sector; larger, more stable companies fared better than growth companies, smaller and research stage ones. An important development, however, was that the negative trend was broken in the middle of the month when biotechnology and smaller companies began to recover. However, the presidential campaign in the United States continued to be a major concern; would a Clinton victory give such a tailwind for the Democrats that the entire Congress might go Democrat? Would a Trump win result in significant changes in the healthcare market such as parallel imports of pharmaceuticals and a significant reduction of Obamacare? Despite the initial recovery within healthcare, these types of questions challenged investors and the sector's recovery showed to be more tentative relative to other sectors. The prevailing consensus is that Congress will (have to) do something about healthcare, such as the high "out-of-pocket" costs that many Medicare patients are faced with, despite Obamacare specifically reducing it in part. Such reforms will have to be financed. The industry will have to pay some of it and the question is how much it will cost in terms of additional discounts and whether or not free pricing will be restricted in conjunction.

The reporting season for healthcare was mediocre or perhaps even somewhat disappointing. The strong dollar gave substantial headwinds for US companies and sales growth was modest. Emerging markets are slowing in terms of volume growth and companies also face weak currencies; meanwhile the opportunities for price increases in the US are perceived to be limited, at least for the rest of the year. Relatively few shares rose on company



#### The Investment Manager is under the supervision of The Swedish Financial Supervisory Authority (Finansinspektionen) as of February 2009

# FEBRUARY 2016


February 2016	YTD Return	Since Inception <sup>1</sup>
-5.40%	-22.90%	226.39%
-5.40%	-22.90%	270.46%
-4.81%	-21.34%	121.76%
-10.90%	-26.41%	86.39%
-5.02%	-22.88%	-19.73%
-4.96%	-22.80%	7.07%
-5.44%	-22.96%	188.23%
-4.89%	-21.47%	174.97%
-4.84%	-21.41%	183.80%
-0.01%	-0.02%	3.84%
	2016 -5.40% -5.40% -4.81% -10.90% -5.02% -4.96% -5.44% -4.89% -4.84%	2016 Return -5.40% -22.90% -5.40% -22.90% -4.81% -21.34% -10.90% -26.41% -5.02% -22.88% -4.96% -22.80% -5.44% -22.96% -4.89% -21.47% -4.84% -21.41%

#### RISK (IC1 EUR)

### EXPOSURE

Value at Risk <sup>2</sup>	3.29%	Long	148%
Standard	22.33%	Short	30%
Deviation <sup>3</sup>	22.33%	Gross	178%
Sharpe Ratio <sup>3</sup>	0.84	Net	117%

#### **CURRENCY EXPOSURE 4**



#### LARGEST LONG POSITIONS

# AUM 5

1 Gilead Sciences Inc	Fund:
2 Alkermes Plc	EUR 409m
3 Pfizer Inc	USD 444m
4 Shire Plc	Firm:
5 Merck KGaA	EUR 434m

# PORTFOLIO CONSTRUCTION 6

PYRAMID LEVEL	POSITION SIZE	NO.
High conviction	3%-10%	4
Core holdings	1%-3%	59
Fractional positions	0.5%-1%	36
Candidate holdings	<0.5%	38

#### Notes

- 1. Please find launch date information on page 3 and 4.
- 2. For holdings at month end (95% conf. int, 250 days history).
- 3. Standard deviation and Sharpe ratio are annualized.
- As a percentage of the market value of the long book.
   The AUM is not adjusted for fund inflow at month end.
- 6. Number of long and short equity positions (excluding any ETFs).



results. In fact, there were many cases where shares fell on results, even when their reported profits were in line with expectations or better, and despite the fact that they already had been weak in the period prior. In short, it was one of the most difficult reporting seasons for some time.

February's best contributors were Meda, Biomarin and Gilead. The worst contributions came from Endo, Perrigo and Regeneron. The Swedish specialty pharma company Meda received another takeover bid from Mylan, which this time was accepted by the Board and the share rose sharply toward the bid price with a premium of over 90%. The biotech company Biomarin had fallen substantially over the past six months, partly together with the rest of the biotech market, but also because of a clinical failure in one of their many research programmes within orphan drugs. In February, however, the share received a boost when the market started to anticipate some of the many expected corporate events during the spring, including data from ongoing studies, as well as an R&D-day in April. The biotech giant Gilead, with a market cap much greater than that of Astra Zeneca, traded down to an unbelievably low valuation: a P/E below 7. It is true that it will be difficult for them to achieve anything but a moderate earnings growth rate over the next few years since, in 2014, they carried out the world's most successful drug launch with their hepatitis C drugs Sovaldi/Harvoni, which sold for over 12 billion dollars in their first year. However, the company generates extremely large cash flows, as much as 70% of its own market value over the next 5 years, which gives them plenty of ammunition for possible acquisitions, but also for dividends and share buybacks. The specialty pharma company Endo fell sharply on the last trading day in February after giving lower guidance than expected in their quarterly report, and also announcing that they see an increased risk of lawsuits relating to a med tech product used in prolapse surgery. They therefore made further provisions and chose to close down the affected division. Perrigo, another specialty pharma company, which previously had been the subject of Mylan's takeover interests, reported worse than expected figures, and lowered its guidance for the whole year. Several analysts are now calling the share a "show me story" and the market right now is too myopic to accept that the company expects an improvement in growth no sooner than in the autumn. The biotech company Regeneron, which among other things sells the most successful treatment for age-related macular degeneration, the leading cause of severe vision loss in the western world, reported somewhat lower numbers for the fourth quarter and also gave weaker guidance. 2016 will be an investment year for Regeneron who is in the process of developing new potential blockbusters, which require considerable research and development efforts in the near future.

We believe that the recovery has begun for the sector. It could, however, be jagged and it cannot be ruled out that the market may want to re-test the lows seen in February. We are convinced that the positives clearly outweigh the negatives. The market has been through a severe test and come through, of course at a considerable cost. Valuations are now at their most attractive for many years, excesses in the markets are gone (illustrated by the fact that there are basically no IPOs), fears over policies in the US after the election are well illuminated and according to our judgment discounted, while a slowdown in emerging markets has already taken place and been priced in. The growth of the global pharmaceutical market has come down a few percentage points (due to the slowdown in emerging markets) and is now back at about the long term trend. However, as a result of the high volatility and uncertainty prior to the US election, the Fund has reduced its net exposure. We continue to give priority to companies that are less affected by the upcoming election results in the United States, albeit that a significant such exposure is inherent in a healthcare sector fund with a large number of US companies. The P/E ratio for the sector is now about 16, which is in line with a global index. The fund's P/E ratio is about the same if research companies and companies with extremely high P/E ratios are excluded (slightly over 20% of the fund). We are convinced that this valuation is very attractive for the long-term investor, considering it is unlikely that the commercial structure of American healthcare and pharmaceutical industry will change fundamentally. The US will continue to be a large, growing and profitable market for the sector.

	MINIMUM INVESTMENT	MGT. FEE	PERF. FEE	ISIN NUMBER	BLOOMBERG TICKER	LIPPER REUTERS	TELEKURS
INSTITUTIONAL S	SHARE CLASSES						
IC1 (EUR)	250,000	1.50%	20%	LU0417598108	RHLEIC1 LX	65147588	10034579
IC3 (EUR)	5,000,000	1.50%	10%	LU0434614789	RHHCIC3 LX	68014068	10283697
IC2 (SEK)	50,000,000	1.00%	20%	LU0417598793	RHHIC2S LX	68204997	20323930
ID1 (SEK)	100,000	1.50%	20%	LU0417599098	RHHCID1 LX	68153820	18491109
IC1 (USD)	300 000	1.50%	20%	LU0417598280	RHUIC1A LX	68305812	26812813
IC2 (USD)	6,000,000	1.00%	20%	LU0417598520	RHUIC2U LX	68265724	24456000
RETAIL SHARE CL	ASSES						
RC1 (EUR)	2,500	2.00%	20%	LU0417597555	RHLERC1 LX	65147589	10034567
RC1 (SEK)	500	2.00%	20%	LU0417597712	RHLSRC1 LX	68014067	10239523
RC2 (SEK)	2,500,000	1.50%	20%	LU0417598017	RHLSRC2 LX	68015239	10239528

The Investment Manager is under the supervision of The Swedish Financial Supervisory Authority (Finansinspektionen) as of February 2009

#### **FUND CHARACTERISTICS**

# **INVESTIBLE CURRENCIES**

Euro (EUR) / Swedish Krona (SEK) / US Dollar (USD)

#### TARGET FUND SIZE

EUR 500m (soft close) EUR 1bn (hard close)

#### RETURN TARGET

Annualised net returns in excess of 12% with volatility below the market

# **LEGAL STRUCTURE**

FCP (Fonds Commun de Placement) under Part II of the Luxembourg Law on Investment Funds

# PORTFOLIO MANAGER

Rhenman & Partners Asset Management AB

# MANAGEMENT COMPANY / AIFM

SEB Fund Services S.A.

#### PRIME BROKER

Skandinaviska Enskilda Banken AB (publ)

# **DEPOSITARY AND PAYING AGENT**

Skandinaviska Enskilda Banken S.A.

#### **EXTERNAL AUDITOR**

PricewaterhouseCoopers (PwC)

# SUBSCRIPTION / REDEMPTION

Monthly

#### **NOTICE PERIOD**

3 working days

#### **HURDLE RATE**

Euribor 90D

# MINIMUM TOP UP

No minimum

Chief Investment Officer HENRIK RHENMAN

Managing Director GÖRAN NORDSTRÖM

Head of Investor Relations

#### **CARL GREVELIUS**

Tel +46 8 459 88 83 Mob +46 768 438 803 carl@rhepa.com

Strandvägen 5A 114 51 Stockholm Sweden



HISTORICAL	RETURNS AN	ID NAVS											
IC1 (EUR) NAV YEAR 2009	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OKT	NOV	DEC	
2010	117.91	119.94	127.53	122.31	108.73	100.75 106.40	105.19 102.84	107.47 102.63	107.83 109.95	100.99 112.16	105.70 116.17	113.28 122.73	
2011	121.53	124.28	123.35	127.79	134.24	129.26	128.19	119.36	118.28	125.67	127.48	134.59	
2012	142.42	143.99	149.51	150.29	150.07	159.07	160.74	160.74	165.47	156.93	161.34	158.92	
2013 2014	168.92 263.91	178.11 277.13	191.91 262.34	198.41 247.80	209.10 260.99	202.53 274.87	225.87 276.25	223.66 296.82	233.45 304.03	225.66 326.16	246.67 338.66	246.79 352.48	
2015	391.34	419.34	448.65	421.01	463.44	456.29	476.60	424.39	370.76	401.72	430.21	423.32	
2016	345.01	326.39											
IC1 (EUR) PERFORM													
YEAR 2009	JAN	FEB	MAR	APR	MAY	JUN 0.75	JUL 4.41	<b>AUG</b> 2.17	SEP 0.33	<b>OKT</b> -6.34	NOV 4.66	<b>DEC</b> 7.17	TOTAL
2010	4.09	1.72	6.33	-4.09	-11.10	-2.14	-3.35	-0.20	7.13	2.01	3.58	5.65	13.28 8.34
2011	-0.98	2.26	-0.75	3.60	5.05	-3.71	-0.83	-6.89	-0.90	6.25	1.44	5.58	9.66
2012	5.82	1.10	3.83	0.52	-0.15	6.00	1.05	0.00	2.94	-5.16	2.81	-1.50	18.08
2013 2014	6.29	5.44	7.75	3.39	5.39	-3.14	11.52	-0.98	4.38	-3.34	9.31	0.05	55.29
2014	6.94 11.02	5.01 7.15	-5.34 6.99	-5.54 -6.16	5.32 10.08	5.32 -1.54	0.50 4.45	7.45 -10.95	2.43 -12.64	7.28 8.35	3.83 7.09	4.08 -1.60	42.83 20.10
2016	-18.50	-5.40											-22.90
IC2 (SEK) NAV													
YEAR	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OKT	NOV	DEC	
2013 2014	105.95 169.27	109.53 178.14	117.11 170.53	123.34 162.83	131.02 172.56	128.83 182.30	142.56 184.56	142.09 197.44	147.55 201.10	144.39 218.77	159.03 227.47	158.77 240.91	
2015	264.32	283.76	300.86	285.57	313.96	305.90	326.08	292.97	252.07	273.89	288.10	281.94	
2016	232.96	221.76											
IC2 (SEK) PERFORM			MID	ADD	MAY	IIII		AUO	OFP	OVT	Nov	DEO	TOTAL
YEAR 2013	<b>JAN</b> 5.95	FEB 3.38	MAR 6.92	APR 5.32	MAY 6.23	JUN -1.67	JUL 10.66	AUG -0.33	SEP 3.84	<b>OKT</b> -2.14	NOV 10.14	-0.16	<b>TOTAL</b> 58.77
2014	6.61	5.24	-4.27	-4.52	5.98	5.64	1.24	6.98	1.85	8.79	3.98	5.91	51.74
2015	9.72	7.35	6.03	-5.08	9.94	-2.57	6.60	-10.15	-13.96	8.66	5.19	-2.14	17.03
2016	-17.37	-4.81											-21.34
IC1 (USD) NAV YEAR	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OKT	NOV	DEC	
2015	JAN	106.43	109.37	107.12	114.84	114.48	118.78	107.70	93.74	100.50	102.88	104.09	
2016	84.51	80.27											
IC1 (USD) PERFORM				400				4410	050	OVE	New	250	7074
YEAR 2015	JAN	FEB 6.43	MAR 2.76	APR -2.06	<b>MAY</b> 7.21	JUN -0.31	JUL 3.76	AUG -9.33	SEP -12.96	<b>OKT</b> 7.21	NOV 2.37	DEC 1.18	<b>TOTAL</b> 4.09
2016	-18.81	-5.02	2.70	-2.00	7.21	-0.51	3.70	-3.55	-12.30	7.21	2.01	1.10	-22.88
IC2 (USD) NAV													
YEAR	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OKT	NOV	DEC	
2014 2015	132.75	141.32	145.96	143.02	102.92 153.38	108.60 152.95	106.82 158.76	113.71 143.26	112.69 124.74	120.10 133.79	124.21 137.03	126.40 138.70	
2016	112.66	107.07	143.30	140.02	100.00	132.33	130.70	140.20	124.74	155.75	107.00	130.70	
IC2 (USD) PERFORM	MANCE %. NET OF FE	ES											
YEAR	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OKT	NOV	DEC	TOTAL
2014 2015	5.02	6.46	3.28	-2.01	2.92 7.24	5.52 -0.28	-1.64 3.80	6.45 -9.76	-0.90 -12.93	6.58 7.26	3.42 2.42	1.76 1.22	26.40 9.73
2016	-18.77	-4.96	3.20	-2.01	1.27	-0.20	3.00	-3.70	-12.33	7.20	2.72	1.22	-22.80
IC3 (EUR) NAV													
YEAR	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OKT	NOV	DEC	
2009 2010	114.20	116.43	124.73	119.62	106.33	104.06	100.57	102.15 100.37	103.33 107.52	96.78 109.68	101.30 113.59	109.19 120.00	
2011	118.82	121.50	120.59	124.92	131.89	126.43	125.36	116.73	115.66	122.76	124.53	132.03	
2012	140.67	142.42	148.58	149.43	149.16	159.24	161.09	161.06	166.38	157.79	162.21	159.79	
2013	170.25	180.70	196.39	203.85	216.23	208.50	235.66	233.03	244.50	236.34	260.09	260.40	
2014 2015	280.76 437.99	296.58 471.80	279.47 508.68	263.97 477.10	278.02 527.32	294.48 518.14	296.09 544.00	321.00 481.68	329.83 420.82	356.89 455.95	372.31 488.29	389.50 480.47	
2016	391.59	370.46	300.00		-252	2.0.14	250	.050	.20.02	.00.00	.00.20	.00.41	
IC3 (EUR) PERFORM													
YEAR 2009	JAN	FEB	MAR	APR	MAY	JUN	JUL	<b>AUG</b> 2.15	SEP 1.16	<b>OKT</b> -6.34	NOV 4.67	<b>DEC</b> 7.79	<b>TOTAL</b> 9.19
2010	4.59	1.95	7.13	-4.10	-11.11	-2.13	-3.35	-0.20	7.12	2.01	3.56	5.64	9.19
2011	-0.98	2.26	-0.75	3.59	5.58	-4.14	-0.85	-6.88	-0.92	6.14	1.44	6.02	10.03
2012	6.54	1.24	4.33	0.57	-0.18	6.76	1.16	-0.02	3.30	-5.16	2.80	-1.49	21.03
2013 2014	6.55 7.82	6.14 5.63	8.68 -5.77	3.80 -5.55	6.07 5.32	-3.57 5.92	13.03 0.55	-1.12 8.41	4.92 2.75	-3.34 8.20	10.05 4.32	0.12 4.62	62.96 49.58
2014	12.45	7.72	-5.77 7.82	-5.55 -6.21	10.53	-1.74	4.99	-11.46	-12.63	8.35	7.09	-1.60	23.36
2016	-18.50	-5.40											-22.90
ID1 (SEK) NAV	,		.,,,							200			
YEAR 2012	JAN	FEB	MAR	APR	MAY 100.64	JUN 104.51	JUL 101.00	AUG 100.77	SEP 105.42	<b>OKT</b> 101.93	NOV 105.47	DEC 103.07	
2012	109.66	109.21	116.69	122.83	130.33	104.51 127.88	141.46	140.87	105.42	143.04	105.47 157.52	103.07	
2014	167.54	168.39	161.54	154.18	163.36	172.51	174.59	186.71	190.10	206.73	214.90	227.49	
2015	249.52	256.41	271.30	257.41	282.93	275.68	293.76	263.61	226.72	246.24	258.91	253.27	
2016	209.19	186.39											

3.85

-1.88

5.60

-2.56

-3.36

10.62

1.21

6.56

-0.23

-0.42

6.94

-10.26

4.61

3.81

1.82

-13.99

-3.31

-2.19

8.75

8.61

3.47

10.12

3.95

5.15

-2.28

-0.21

5.86

-2.18

3.07

52.51

44.72

11.33

-26.41

MAY

0.64

6.11

5.95

9.91

ID1 (SEK) PERFORMANCE %. NET OF FEES YEAR

6.39

6.58

9.68

2012

2013

2014

2015

FEB

-0.41

0.51

2.76

-10.90

MAR

6.85

-4.07

5.81

5.26

-4.56

-5.12

2010	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OKT	NOV	DEC	
2010	114.18	116.50	115.79	119.40	125.10	120.47	119.15	110.91	104.35 109.86	104.75 116.68	110.36 118.31	115.32 124.92	
2012	132.14	133.59	138.66	139.34	139.09	147.39	148.89	148.83	153.16	145.20	149.21	146.92	
2013 2014	156.14 240.30	164.59 251.66	177.28 236.42	183.22 223.21	192.89 235.00	185.65 247.45	206.96 248.60	204.86	212.69	205.49 293.13	224.58	224.79	
2014	349.47	373.47	398.19	373.48	411.03	404.45	422.31	266.95 375.75	273.34 328.13	355.37	304.24 380.41	315.14 374.15	
2016	304.81	288.23											
RC1 (EUR) PERFORM			MAD	ADD	MAY			4110	OFP	OVT	Nov	DEO	TOTAL
YEAR 2010	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP 4.35	<b>OKT</b> 0.38	NOV 5.36	<b>DEC</b> 4.49	<b>TOTAL</b> 15.32
2011	-0.99	2.03	-0.61	3.12	4.77	-3.70	-1.10	-6.92	-0.95	6.21	1.40	5.59	8.32
2012	5.78	1.10	3.80	0.49	-0.18	5.97	1.02	-0.04	2.91	-5.20	2.76	-1.53	17.61
2013 2014	6.28 6.90	5.41 4.73	7.71 -6.06	3.35 -5.59	5.28 5.28	-3.75 5.30	11.48 0.46	-1.01 7.38	3.82 2.39	-3.39 7.24	9.29 3.80	0.09 3.58	53.00 40.19
2015	10.89	6.87	6.62	-6.21	10.05	-1.60	4.42	-11.03	-12.67	8.30	7.05	-1.65	18.73
2016	-18.53	-5.44											-22.96
RC1 (SEK) NAV YEAR	IAN	CCD	MAD	ADD	MAY	IIIN	1111	AUC	ern	OVT	NOV	DEC	
2009	JAN	FEB	MAR	APR	MAY	JUN 99.74	JUL 99.92	AUG 101.00	SEP 101.51	<b>OKT</b> 96.72	NOV 101.85	DEC 106.75	
2010	110.70	108.05	115.09	109.18	96.69	93.87	89.69	88.93	93.37	96.59	98.29	102.16	
2011	98.91	100.22	101.80	105.28	111.04	109.04	107.03	100.09	100.29	104.24	106.42	111.05	
2012 2013	118.78 136.76	118.87 141.24	123.79 150.89	125.05 158.78	125.79 168.47	130.61 165.25	126.17 182.72	125.85 181.89	131.65 188.61	127.25 184.41	131.60 203.02	128.55 202.38	
2014	215.63	226.61	216.26	206.33	218.55	230.73	233.43	249.55	253.98	276.09	286.74	302.97	
2015	332.20	356.11	376.45	357.02	392.32	381.98	406.89	365.09	313.86	340.74	358.11	350.16	
2016 RC1 (SEK) PERFORM	289.10	274.97											
YEAR	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OKT	NOV	DEC	TOTAL
2009						-0.26	0.18	1.08	0.50	-4.72	5.30	4.81	6.75
2010	3.70	-2.39	6.52	-5.14	-11.44	-2.92	-4.45	-0.85	4.99	3.45	1.76	3.94	-4.30
2011 2012	-3.18 6.96	1.32 0.08	1.58 4.14	3.42 1.02	5.47 0.59	-1.80 3.83	-1.84 -3.40	-6.48 -0.25	0.20 4.61	3.94 -3.34	2.09 3.42	4.35 -2.32	8.70 15.76
2013	6.39	3.28	6.83	5.23	6.10	-1.91	10.57	-0.25	3.69	-2.23	10.09	-0.32	57.43
2014	6.55	5.09	-4.57	-4.59	5.92	5.57	1.17	6.91	1.78	8.71	3.86	5.66	49.70
2015	9.65	7.20	5.71	-5.16	9.89	-2.64	6.52	-10.27	-14.03	8.56	5.10	-2.22	15.58
RC2 (SEK) NAV	-17.44	-4.89											-21.47
YEAR	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OKT	NOV	DEC	
2009						99.74	99.98	101.12	101.68	96.94	102.10	107.07	
2010	111.07 99.84	108.57	115.69	109.78	97.28	94.47	90.31	89.58	94.10	97.38	99.14	103.08	
2011 2012	120.30	101.20 120.44	102.84 125.51	106.40 126.83	112.28 127.66	110.30 132.58	108.32 128.13	101.33 127.86	101.58 133.77	105.64 129.36	107.89 133.84	112.63 130.80	
2013	139.17	143.74	153.48	161.57	171.53	167.92	185.74	185.04	192.06	187.86	206.87	206.39	
2014	219.98	231.28	221.05	210.98	223.54	236.05	238.90	255.47	260.24	283.00	293.97	310.92	
2015 2016	341.02 298.25	365.80 283.80	386.77	366.96	403.34	392.85	418.61	375.87	323.26	351.09	369.14	361.10	
RC2 (SEK) PERFORM													
YEAR	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OKT	NOV	DEC	TOTAL
2009	2.74	2.25	0.50	F 11	11.20	-0.26	0.24	1.14	0.55	-4.66	5.32	4.87	7.07
2010 2011	3.74 -3.14	-2.25 1.36	6.56 1.62	-5.11 3.46	-11.39 5.53	-2.89 -1.76	-4.40 -1.80	-0.81 -6.45	5.05 0.25	3.49 4.00	1.81 2.13	3.97 4.39	-3.73 9.26
2012	6.81	0.12	4.21	1.05	0.65	3.85	-3.36	-0.21	4.62	-3.30	3.46	-2.27	16.13
2013	6.40	3.28	6.78	5.27	6.16	-2.10	10.61	-0.38	3.79	-2.19	10.12	-0.23	57.79
2014 2015	6.58 9.68	5.14 7.27	-4.42 5.73	-4.56 -5.12	5.95 9.91	5.60 -2.60	1.21 6.56	6.94 -10.21	1.87 -14.00	8.75 8.61	3.88 5.14	5.77 -2.18	50.65 16.14
2016	-17.41	-4.84	00	0.12	0.01	2.00	0.00		1 1.00	0.01	0	20	-21.41
LEGAL DISCL	LAIMER												
			is not an investn				publication if error the accuracy of its		nions or informat	tion change. Rhen	man & Partners a	ccepts no respor	nsibility for
regarding Fund is	contained in the	Prospectus and	the KIID. available	e at Rhenman &			Rhenman & Partn		f all works of aut	thorship including	but not limited	to all design to	yt images
					£		and trademarks in	this material unle	ss otherwise expl	licitly stated. The	use of Rhenman	& Partners' mate	rial, works
& Partners when	preparing this inf	formation has no	rtners for profession ot taken into accou	unt any one custo	omer's particular	investment	or trademarks is f prohibited to publ						more, it is
			cumstances and the rticular investment				By accessing and	using the http://r	hepa.com/ webs	ite and any page	s thereof, you a	cknowledge that	you have
	represent recomm		strued as an offer of	or solicitation to s	sell or buy units th	e Fund.	reviewed the follo therein. If you						
not intended to r		ould not be cons			rco or uponticinat	ed market	http://rhepa.com/						
not intended to r informational pur All securities' trar	rposes only and sh	risks, which inclu	ide (among others					reporte in any ma					
not intended to r informational pur All securities' trar financial or politic an investment in	rposes only and sh nsactions involve o cal developments the Fund will ach	risks, which inclu and, in internation nieve profits or a	onal transactions, woid incurring sub	currency risk. The	ere can be no assi There is a high de	urance that gree of risk	Products and serv	ices described her					
not intended to r informational pur All securities' tra financial or politic an investment in inherent in inves	rposes only and sh nsactions involve is cal developments the Fund will ach tments and they is	risks, which inclu and, in internation nieve profits or a may not be suita	onal transactions,	currency risk. The estantial losses. T investors. It is p	ere can be no assi There is a high de possible that an in	urance that gree of risk vestor may		ices described her ovide any such pr	oducts or service	es to any person	if the provision o	f such services o	ould be in
not intended to r informational pur All securities' trar financial or politic an investment in inherent in invest lose some or all I The value of inve	rposes only and should be reactions involved and developments the Fund will ach the fund the	risks, which inclu and, in internation nieve profits or a may not be suita The past is not n as well as rise an	onal transactions, avoid incurring sub able for all eligible necessarily a guide nd investors may n	currency risk. The estantial losses. To investors. It is post to the future per not get back the a	ere can be no assu There is a high de possible that an in erformance of an i	urance that gree of risk vestor may nvestment.	Products and serv Partner will not pr violation of law or of the Fund may n	ices described her rovide any such pr regulation in such ot be offered or so	oducts or service person's home o old to or within t	es to any person country jurisdictio the United States	if the provision on or any other re	f such services c lated jurisdiction	ould be in . The units
not intended to r informational pur All securities' tran financial or politid an investment in inherent in inves lose some or all of The value of inve rates of foreign es	rposes only and sh nsactions involve ical developments the Fund will ach tments and they of its investment. Isstments may fall is exchange may caus	risks, which inclu and, in internation nieve profits or a my not be suits The past is not n as well as rise an se the value of in	onal transactions, avoid incurring sub able for all eligible necessarily a guide nd investors may n vestments to go u	currency risk. The stantial losses. I investors. It is put to the future period get back the apport down.	ere can be no assi There is a high de lossible that an in erformance of an i amount invested.	urance that gree of risk vestor may nvestment. Changes in	Products and serv Partner will not priviolation of law or of the Fund may not sale would conflict	ices described her ovide any such pr regulation in such ot be offered or so with applicable la	person's home of person's home of old to or within t ws or regulations	es to any person country jurisdictio the United States	if the provision on n or any other re or in any other c	of such services of lated jurisdiction ountry where su	ould be in . The units ch offer or
not intended to r informational pur All securities' tran financial or politic an investment in inherent in inves lose some or all ( The value of inve rates of foreign er Before making a investments in th	rposes only and she negatives involve is call developments the Fund will ach treents and they in fits investment. estments may fall is xchange may caus an investment de ne Fund with resp	risks, which inclu and, in internatin ileve profits or a may not be suita The past is not n as well as rise ar ise the value of investing ecision, an investing ecit to its investr	onal transactions, avoid incurring subside for all eligible lecessarily a guide and investors may no vestments to go upstor and/or its aument objectives aument objectives are	currency risk. The stantial losses. The stantial losses. It is put to the future periot get back the apport down.  dviser should (i) and personal situations.	ere can be no assiftere is a high depossible that an inerformance of an improvement invested.  I consider the subtion and (ii) consider on the subtion and (ii) consider the subtion and (ii) consider the subtion and (ii) consider the subtion and (iii) consider the subtion and (iiii) consider the subtion and (iiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiii	greance that gree of risk vestor may nvestment. Changes in hitability of der factors	Products and serv Partner will not proviolation of law or of the Fund may not sale would conflict In no event, including consequential	ices described her rovide any such pr regulation in such of the offered or so with applicable la ding (but not limite	roducts or service person's home cold to or within t ws or regulations ed to) negligence	es to any person country jurisdictio the United States s. e, will Rhenman &	if the provision on or any other re or in any other or Partner be liable	of such services of lated jurisdiction ountry where such to you or anyon	ould be in . The units ch offer or ne else for
not intended to r informational pur All securities' trat financial or politic an investment in inherent in invest lose some or all c The value of inver rates of foreign e: Before making a investments in the	rposes only and she neactions involve is cal developments the Fund will ach treents and they of its investment. estments may fall exchange may caus an investment do an investment do the Fund with responal net worth, inco-	risks, which inclu and, in internation ineve profits or a may not be suita The past is not n as well as rise ar ise the value of invection, an inves- ection, an investrome, age, risk to	onal transactions, avoid incurring subable for all eligible necessarily a guide nd investors may no vestments to go upstor and/or its australia.	currency risk. The stantial losses. The stantial losses. It is put to the future periot get back the apport down.  dviser should (i) and personal situality needs. Short-	ere can be no assi there is a high de, cossible that an in informance of an i amount invested. I consider the su tition and (ii) consi- term investors an	urance that gree of risk vestor may nvestment. Changes in uitability of der factors d investors	Products and serve Partner will not puriolation of law or of the Fund may resale would conflict.  In no event, include the products and server in the product in t	ices described her rovide any such pr regulation in such of the offered or so with applicable la ding (but not limite	roducts or service person's home cold to or within t ws or regulations ed to) negligence	es to any person country jurisdictio the United States s. e, will Rhenman &	if the provision on or any other re or in any other or Partner be liable	of such services of lated jurisdiction ountry where such to you or anyon	ould be in . The units ch offer or ne else for
not intended to r informational pur All securities' trat financial or politic an investment in inherent in invest lose some or all c The value of inver rates of foreign e: Before making a investments in the	poses only and sh nsactions involve ical developments the Fund will act tments and they if of its investment. stments may fall in xchange may caus an investment de ne Fund with resp and in the worth, inco	risks, which inclu and, in internation ineve profits or a may not be suita The past is not n as well as rise ar ise the value of invection, an inves- ection, an investrome, age, risk to	onal transactions, avoid incurring sub able for all eligible elecessarily a guide investors may no vestments to go up stor and/or its aument objectives and lerance, and liquice.	currency risk. The stantial losses. The stantial losses. It is put to the future periot get back the apport down.  dviser should (i) and personal situality needs. Short-	ere can be no assi there is a high de, cossible that an in informance of an i amount invested. I consider the su tition and (ii) consi- term investors an	urance that gree of risk vestor may nvestment. Changes in uitability of der factors d investors	Products and serv Partner will not priviolation of law or of the Fund may not sale would conflict In no event, including consequential and damages).	ices described her rovide any such pr regulation in such ot be offered or so with applicable la ling (but not limite , incidental, specia	oducts or service person's home of old to or within t ws or regulations ed to) negligence al or indirect dan purchase of shar	es to any person country jurisdiction the United States companies. e, will Rhenman & enages (including b	if the provision on or any other re or in any other contact and the provision of the provis	if such services of lated jurisdiction ountry where sure to you or anyou lost profits, tractions is the l	ould be in . The units ch offer or ne else for ding losses atest valid
not intended to r informational pur All securities' trat financial or politic an investment in inherent in inves- lose some or all c The value of inve- rates of foreign es- investments in th such as its persor who cannot bear investment shoul  Due care and att	rposes only and sh nsactions involve ical developments the Fund will ach the fund will ach stitute in the street was an investment. stype may fall stype may fall stype may fall stype may fall stype may fall an investment de ne Fund with resp nath the loss of some id not invest.	risks, which inclu and, in internation internation or a may not be suited The past is not n as well as rise are ise the value of invection, an invec- ect to its investre ome, age, risk to or all of their invection or all of their invection.	onal transactions, avoid incurring sub able for all eligible becessarily a guide di investors may no vestments to go up stor and/or its amelerance, and liquic vestment or the riparation of this in paration of this in paration of this in	currency risk. Th stantial losses. T. investors. It is p to the future pe of get back the approximation of portion. dviser should (i) and personal situal dity needs. Short- sks associated w formation. Howe	ere can be no assiftere is a high dej cossible that an in rformance of an i amount invested.  I consider the suction and (ii) cossisterm investors an ith the limited liquever, actual results	urance that gree of risk vestor may nivestment. Changes in itiability of der factors d investors uidity of an	Products and serv Partner will not proviolation of law or of the Fund may neale would conflict In no event, including consequential and damages).  The sole legally bit sales prospectus w	ices described her rovide any such pr regulation in such of be offered or s with applicable la ding (but not limit, incidental, special anding basis for the ith its terms of cor	person's home of person's home of person's home of the way or regulations and to head	es to any person country jurisdictio the United States s. e, will Rhenman & nages (including to res of the Fund de ons cannot be rec	if the provision of n or any other re or in any other c  Partner be liable but not limited to scribed in this inteved on the basi	If such services clated jurisdiction ountry where such that is a to you or anyou lost profits, traction is the lost of financial reposits.	ould be in . The units ch offer or one else for ding losses atest valid orts.
not intended to r informational pur All securities' trai financial or politic an investment in inherent in inves lose some or all ic The value of inve rates of foreign e: Before making a investments in th such as its persor who cannot bear investment shoul  Due care and att from their foreca	rposes only and sh nsactions involve I cal developments the Fund will act the Fund will act of its investment. ststments may fall: xchange may caus an investment de ne Fund with resp nal net worth, inco the loss of some d not invest.	risks, which inclu and, in internation internation or a may not be suita. The past is not nas well as rise ar ise the value of im- ecision, an inves- ect to its investrome, age, risk to or all of their investrome, age, risk to	onal transactions, avoid incurring suble for all eligible becessarily a guide di unvestors may no vestments to go ul stor and/or its allerance, and liquic vestment or the rivestment or the rivestment or the rivestment or the rives allerance, and liquic vestment or the rivestment or rives	currency risk. This stantial losses. This stantial losses. The stantial losses investors. It is put to the future per to get back the appropriate of the stantial losses. Adviser should (i) Indipersonal situality needs. Shortsks associated with the stantial losses with the stantial losses with the stantial losses with the stantial losses with the stantial losses. The stantial losses with the stantial losses with the stantial losses with the stantial losses. The stantial losses with the stantial losses with the stantial losses. The stantial losses with the stantial losses with the stantial losses with the stantial losses. The stantial losses with the stantial losse	ere can be no assistered in the rein a high depossible that an in reformance of an i amount invested.  I consider the suttion and (ii) consisterm investors an ith the limited liquever, actual result sts, by their very	urance that gree of risk vestor may nestment. Changes in hitability of der factors d investors uidity of an s may vary nature, are	Products and serv Partner will not priviolation of law or of the Fund may not sale would conflict In no event, including consequential and damages).	ices described her rovide any such pr regulation in such of be offered or si with applicable la lding (but not limite i, incidental, special inding basis for the ith its terms of con in this document v	oducts or service person's home e old to or within it ws or regulations ed to) negligence all or indirect dan purchase of shar ntract. Subscription	es to any person country jurisdiction the United States is.  e, will Rhenman & mages (including but the Fund de cons cannot be recons Rhenman & Pai	if the provision on or any other re or in any other or Partner be liable out not limited to scribed in this interved on the basistners Asset Mar	of such services c lated jurisdiction ountry where sur- e to you or anyon lost profits, trac- formation is the l s of financial repre- nagement AB (RI	ould be in . The units ch offer or me else for ding losses atest valid orts.
not intended to r informational pur All securities' trat financial or politic an investment in inherent in inves- lose some or all c The value of inve- rates of foreign es investments in th such as its persor who cannot bear investment shoul  Due care and att from their foreca subject to uncert- & Partners canno	rposes only and sh nsactions involve ical developments the Fund will ach the fund will ach of its investment. stsments may facus an investment de ne Fund with resp nal net worth, inco- the loss of some id not invest. tention has been sts, and any varia ainty and conting it guarantee that it	risks, which inclu and, in internati nieve profits or a may not be suite may not be suite he past is not n as well as rise ar ie the value of in ecision, an inve- ecet to its investr ome, age, risk to or all of their in used in the pre- tion may be mat encies, many of w he information of	onal transactions, substituted in the state of the state	currency risk. The sistantial losses. The investors, it is per to the future per to the future per to get back the inportant per to the per to down. It is per to the future per to get per	ere can be no assisted in the reis a high dej hossible that an in riformance of an i amount invested.  I consider the subtion and (ii) consi- term investors an ith the limited liquities, by their very ever, actual result stss, by their very entirely accurate.	urance that gree of risk vestor may nvestment. Changes in littability of ider factors d investors uidity of an s may vary nature, are i. Rhenman There may	Products and serv Partner will not proviolation of law or of the Fund may n sale would conflict In no event, including consequential and damages).  The sole legally bis sales prospectus with the province of the partners of the partners of the contains of the province of	ices described her royide any such pr regulation in such of the offered or s with applicable la ling (but not limiti, incidental, specia and ing basis for the ith its terms of cor n this document uld not be conside s general informa	person's home cold to or within two or regulations ed to) negligence al or indirect dan purchase of sharntract. Subscriptic was prepared by erred a recommer tition only and dr.	es to any person country jurisdictio the United States c, will Rhenman & nages (including t es of the Fund de ons cannot be rec y Rhenman & Pai dation to purcha bes not take acco	if the provision or or any other re or in any other cor in any other correct corre	if such services of lated jurisdiction ountry where sur- e to you or anyon lost profits, trac- formation is the le s of financial repo- nagement AB (RI uny particular sec- vidual objectives	ould be in . The units ch offer or ne else for ding losses atest valid orts. henman & surity. This is, financial
not intended to r informational pur  All securities' trat financial or politic an investment in inherent in invess lose some or all c The value of inve- rates of foreign er ations and sing a investments in th such as its persor who cannot bear investments shoul  Due care and att from their foreca subject to uncert. & Partners canno be delays, omissi	rposes only and sh nsactions involve I cal developments the Fund will ad- timents and they I of its investment. ststments may fall i sxchange may caus an investment de ne Fund with resp nal net worth, inco the loss of some d not invest. tention has been sts, and any varia ainty and conting it guarantee that it or grander that it or grander that it or grander that it or grander that it or grander that it or grander that it or grander that it or grander that it or grander that it or grander that it or grander that it or grander that it or gr	risks, which inclu and, in internation internation or a may not be suita. The past is not nas well as rise are the tetral of internation or a ection, an invest ect to its investrome, age, risk to or all of their internation or used in the preption may be matencies, many of vehicinformation of est in the information of sets in the information of est in the information of sets in the information of	onal transactions, vooid incurring sud bable for all eligible secessarily a guide di investors may n vestments to go u! ment objectives an enert objectives an lerance, and liquic vestment or the ri paration of this in terially positive or which are outside!	currency risk. Th stantial losses. The stantial losses. It is p to the future pe ot get back the is or down. dviser should (i) Id personal situal lity needs. Short- sks associated w formation. Howe negative. Foreca the control of Rh without fault or formation is pub	ere can be no assifthere is a high dej here is a high dej ossible that an in rformance of an i amount invested.  I consider the sutition and (ii) consisterm investors an ith the limited liquever, actual result sts, by their very enman & Partner entirely accurate. Iished as of its dai	urance that gree of risk vestor may nvestment. Changes in littability of ider factors d investors uidity of an s may vary nature, are i. Rhenman There may	Products and serv Partner will not puviolation of law or of the Fund may n sale would conflict In no event, inclurany consequential and damages).  The sole legally bis sales prospectus w The information i Partners) and sho document contair situation or needs regard to your par	ices described her royide any such pr regulation in such of be offered or s with applicable la ling (but not limite, incidental, special inding basis for the rith its terms of cor n this document uld not be conside s general informa You should get p ticular investment	roducts or service person's home cold to or within the way or regulations and to he may be a few and the way of the way o	es to any person country jurisdictio he United States s. e, will Rhenman & nages (including t res of the Fund de ons cannot be rec r Rhenman & Pan dation to purcha oes not take acce e as to whether ir s and financial cir s and financial cir	if the provision of or any other re or in any other c or in any other c Partner be liable out not limited to scribed in this inteleved on the basisteners Asset Marse, sell or hold a ount of your indivestment in the cumstances before	of such services of lated jurisdiction ountry where sure to you or anyon lost profits, traction of the soft financial reports of financial reports aggement AB (RI my particular secvidual objectives Fund is approprie investing, An in	ould be in . The units ch offer or one else for ding losses atest valid orts.  henman & curity. This , financial ate having nvestment
not intended to r informational pur All securities' trat financial or politic an investment in inherent in inves- lose some or all c The value of inve- rates of foreign e: Before making a investments in t such as its persor who cannot bear investment shoul Due care and att from their foreca subject to uncert & Partners canno be delays, omissi no obligation or r	rposes only and sh nsactions involve ical developments the Fund will ach the fund will ach stitute in the fund will ach of its investment. ststments may fall is xchange may caus an investment de ne Fund with resp nal net worth, inco- the loss of some id not invest. tention has been sts, and any varia ainty and conting it guarantee that to ons or inaccuracie responsibility is un	risks, which inclu and, in internati- nieve profits or a may not be suita. The past is not n as well as rise ar ise the value of im- ecision, an inver- ect to its investrome, age, risk to or all of their im- used in the pre- tion may be mat encies, many of v he information c as in the information c as in the information c as in the information c	onal transactions, void incurring sub bable for all eligible eccessarily a guide di investors may n vestments to go u stor and/or its a ment objectives an lerance, and liquic vestment or the ri paration of this in terially positive or which are outside contained herein is toton. Any dated in the paration of the paration of this in terially positive or which are outside to contained herein is toton. Any dated in the paration of the paration of this in terially positive or which are outside to total paration of this in terially positive or which are outside to total paration of this in terially positive or which are outside to total paration of the paration of paration of this in terially positive or which are outside to total paration . Any dated in total paration total paration	currency risk. The standard losses. The investors. It is put to the future period get back the appropriate properties of the properties of the period get back the appropriate properties. The properties of the p	ere can be no assi fhere is a high dej lossible that an in rformance of an i amount invested.  I consider the su- tion and (ii) consi- term investors an ith the limited lique over, actual result stst, by their very enman & Partners entirely accurate. lished as of its data.	urance that gree of risk vestor may nvestment. Changes in itability of der factors d investors uidity of an as may vary nature, are to Rhenman There may te only and	Products and serv Partner will not puviolation of law or of the Fund may no sale would conflict In no event, including any consequential and damages).  The sole legally bis sales prospectus with the information in Partners) and sho document contains situation or needs	ices described her royide any such pr regulation in such of the offered or s with applicable la ling (but not limiti, incidental, specia and ing basis for the ith its terms of cor n this document uld not be conside segeneral informa You should get p ticular investment not represent der	oducts or service person's home cold to or within t ws or regulations ed to) negligence al or indirect dan purchase of sharntract. Subscriptic was prepared by erred a recommer tion only and drofessional advicenceds, objective soits or other li	es to any person country jurisdiction the United States is. e., will Rhenman & nages (including the season of the Fund deons cannot be read at the season of the season of the season of the season of the access on the season of the access on the season of the access on the season of the access of the season of	if the provision of or any other re or in any other cor in any other corrections.	of such services of lated jurisdiction ountry where sure to you or anyou lost profits, tractions is the lost profits of financial reportangement AB (RI my particular secvidual objectives Fund is approprier investing. An interement & Partner investing. An interest investing and interest investi	ould be in . The units ch offer or one else for ding losses atest valid orts. atest valid orts. This is, financial ate having nivestment ers Group.
not intended to r informational pur All securities' trat financial or politic an investment in inherent in invest lose some or all c The value of inve rates of foreign es investments in t such as its persor who cannot bear investment shoul Due care and att from their foreca subject to uncert. & Partners canno be delays, omissi no obligation or r The information i Partners can how	rposes only and sh nsactions involve ical developments the Fund will ach the fund will ach fits investment. styments may fall is exchange may caus an investment de ne Fund with resp naal net worth, inco the loss of some d not invest. tention has been sts, and any varia ainty and conting it guarantee that to ons or inaccuracie esponsibility is un in this material is vever not guarant	risks, which inclu and, in internati nieve profits or a may not be suita The past is not n as well as rise ar te the value of in ect to its investr ome, age, risk to or all of their im used in the pret tion may be mat tion may be mat encies, many of v the information or es in the informat dertaken to upde based on source tee that all infor	onal transactions, vivid incurring sub- provided in eligible increased in eligible increased in eligible increased in eligible increased in experience in ex	currency risk. The sistential losses. The sistential losses. The tothe future per futur	ere can be no assisted in the reis a high dej horsible that an in informance of an i amount invested.  I consider the substitution and (ii) consi- term investors an ith the limited lique ever, actual result sts, by their very entirely accurate. lished as of its dai  es to be reliable. F formation and op and one of the properties of the constitution of the properties of the properties of the properties of the properties of properties of properties properties of properties of properties of properties of properties of properties p	gree of risk vestor may nvestment. Changes in iitability of der factors d investors uidity of an as may vary nature, are is. Rhenman There may te only and thenman & thenman & thenman way the only and thenman way the only and thenman and thenman way the only and thenman and then and the thenman and the thenman and the thenman and the thenman and the then an	Products and serv Partner will not products and serv Partner will not proviolation of law or of the Fund may no sale would conflict.  In no event, including any consequential and damages).  The sole legally bis sales prospectus with the production of the partners of the	ices described her rovide any such pr regulation in such to the offered or si with applicable la ling (but not limiti, incidental, special hinding basis for the rith its terms of cor luld not be conside segeneral informa You should get procured ticular investment not represent der & Partners nor an promance of the Fu	person's home cold to or within two or regulations ed to) negligence al or indirect dan purchase of shartract. Subscription was prepared by ered a recomment to only and drofessional advicenceds, objective in the promotion of the product of the pr	es to any person country jurisdiction the United States is.  e., will Rhenman & nages (including but on the Fund de ons cannot be reconstant) to purchase the same access as to whether it is and financial cir abilitities of any me Rhenman & Pan e Rhenman	if the provision of or any other re or in any other re or in any other cor in any other corrections of the correction of	of such services of lated jurisdiction ountry where such that the such t	ould be in The units ch offer or  ne else for ding losses atest valid orts. henman & curity. This s, financial ate having nvestment ers Group. rantees in

RC1 (EUR) NAV YEAR